- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00004986
Safety and Effectiveness of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients
June 23, 2005 updated by: Romark Laboratories L.C.
Open Label, Multi-Center Evaluation of Nitazoxanide for the Treatment of Cryptosporidiosis in Subjects With AIDS in the United States
The purpose of this study is to see if it is safe and effective to treat cryptosporidiosis in AIDS patients with nitazoxanide.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Patients take nitazoxanide daily for 8 weeks with a dose escalation after the first 4 weeks.
Patients return to the hospital for examinations every 2 weeks during the 8-week treatment period and 6-week follow-up.
Nitazoxanide therapy is discontinued in patients showing a complete clinical and parasitologic response (therapeutic cure) after 8 weeks of treatment and in patients showing a therapeutic cure at two consecutive visits (Weeks 2 and 4 or Weeks 4 and 6).
These patients undergo a physical examination including stool analysis for Cryptosporidium parvum oocysts and routine laboratory tests at Weeks 2, 4, and 6 after completion of nitazoxanide therapy.
Patients who do not show a complete clinical and parasitologic response (therapeutic failure) after 8 weeks of treatment are allowed to remain on nitazoxanide therapy through the Open Label Compassionate Use of Nitazoxanide in Treatment of Cryptosporidiosis in AIDS Patients (UMD-95-009) protocol.
Study Type
Interventional
Enrollment
30
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33607
- Julie Ryner
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
13 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria
Patients may be eligible for this study if they:
- Are HIV-positive.
- Have a CD4 cell count of 50 cells/mm3 or less.
- Have evidence of cryptosporidium infection in their stool sample within 10 days of study entry.
- Have watery stools at least three times a day at least 5 days a week for 21 days prior to enrollment.
- Are able to take medications by mouth.
- Are at least 13 years old (consent of parent or guardian required if under 18).
- Agree to use an effective method of birth control (such as condoms) during the study.
Exclusion Criteria
Patients will not be eligible if they:
- Have certain diseases or infections of the intestines.
- Have ever taken nitazoxanide.
- Have taken certain experimental drugs within 14 days of enrollment.
- Will need to take certain other medications during the study such as paromomycin, azithromycin, and clarithromycin.
- Have started a new anti-HIV therapy within 4 weeks of study entry or plan on starting one during the study.
- Are pregnant or breast-feeding.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2000
Study Registration Dates
First Submitted
March 16, 2000
First Submitted That Met QC Criteria
August 30, 2001
First Posted (Estimate)
August 31, 2001
Study Record Updates
Last Update Posted (Estimate)
June 24, 2005
Last Update Submitted That Met QC Criteria
June 23, 2005
Last Verified
August 1, 2000
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 253C
- RM-NTZ-99-003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Nitazoxanide
-
Telethon Kids InstituteWithdrawn
-
Azidus BrasilFarmoquimica S.A.; Hospital Vera Cruz; Hospital Casa de Saúde - Vera Cruz - Campinas... and other collaboratorsCompleted
-
Romark Laboratories L.C.CompletedRotavirus Infection | Norovirus Infection | Adenoviridae Infection
-
Azidus BrasilFarmoquimica S.A.Recruiting
-
Maha TalaabCompleted
-
Pinnacle Clinical Research, PLLCCompletedFatty Liver | Fibrosis, Liver | Compensated Cirrhosis | Non-alcoholic SteatohepatitisUnited States
-
Romark Laboratories L.C.CompletedRhinovirus | EnterovirusUnited States, Puerto Rico
-
Materno-Perinatal Hospital of the State of MexicoLaboratorios LiomontCompletedCoronavirus InfectionMexico
-
International Centre for Diarrhoeal Disease Research...University of VirginiaCompleted
-
Sadat City UniversityRecruitingIrritable Bowel Syndrome With DiarrheaEgypt